Browse > Article
http://dx.doi.org/10.4014/jmb.1712.12007

Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness  

Kim, Eun-Ha (Microbiology Department, College of Medicine and Medical Research Institute, Chungbuk National University)
Kwon, Hyeok-Il (Microbiology Department, College of Medicine and Medical Research Institute, Chungbuk National University)
Park, Su-Jin (Microbiology Department, College of Medicine and Medical Research Institute, Chungbuk National University)
Kim, Young-Il (Microbiology Department, College of Medicine and Medical Research Institute, Chungbuk National University)
Si, Young-Jae (Microbiology Department, College of Medicine and Medical Research Institute, Chungbuk National University)
Lee, In-Won (Microbiology Department, College of Medicine and Medical Research Institute, Chungbuk National University)
Kim, Se mi (Microbiology Department, College of Medicine and Medical Research Institute, Chungbuk National University)
Kim, Soo-In (Virus Vaccine, Green Cross Research Center)
Ahn, Dong-Ho (Virus Vaccine, Green Cross Research Center)
Choi, Young-Ki (Microbiology Department, College of Medicine and Medical Research Institute, Chungbuk National University)
Publication Information
Journal of Microbiology and Biotechnology / v.28, no.6, 2018 , pp. 997-1006 More about this Journal
Abstract
As shown during the 2009 pandemic H1N1 (A(H1N1)pdm09) outbreak, egg-based influenza vaccine production technology is insufficient to meet global demands during an influenza pandemic. Therefore, there is a need to adapt cell culture-derived vaccine technology using suspended cell lines for more rapid and larger-scale vaccine production. In this study, we attempted to generate a high-growth influenza vaccine strain in MDCK cells using an A/Puerto/8/1934 (H1N1) vaccine seed strain. Following 48 serial passages with four rounds of virus plaque purification in MDCK cells, we were able to select several MDCK-adapted plaques that could grow over $10^8PFU/ml$. Genetic characterization revealed that these viruses mainly had amino acid substitutions in internal genes and exhibited higher polymerase activities. By using a series of Rg viruses, we demonstrated the essential residues of each gene and identified a set of high-growth strains in MDCK cells ($PB1_{D153N}$, $M1_{A137T}$, and $NS1_{N176S}$). In addition, we confirmed that in the context of the high-growth A/PR/8/34 backbone, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2), and A/environment/Korea/deltaW150/2006 (H5N1) also showed significantly enhanced growth properties (more than $10^7PFU/ml$) in both attached- and suspended-MDCK cells compared with each representative virus and the original PR8 vaccine strain. Taken together, this study demonstrates the feasibility of a cell culture-derived approach to produce seed viruses for influenza vaccines that are cheap and can be grown promptly and vigorously as a substitute for egg-based vaccines. Thus, our results suggest that MDCK cell-based vaccine production is a feasible option for producing large-scale vaccines in case of pandemic outbreaks.
Keywords
Influenza viruses; cell-derived vaccine; Madin-Darby canine kidney (MDCK) cells; bioreactors;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Song M-S, Pascua PNQ, Lee JH, Baek YH, Lee O-J, Kim C-J, et al. 2009. The polymerase acidic protein gene of influenza A virus contributes to pathogenicity in a mouse model. J. Virol. 83: 12325-12335.   DOI
2 Lohr V, Genzel Y, Behrendt I, Scharfenberg K, Reichl U. 2010. A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 28: 6256-6264.   DOI
3 Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27: 493-497.   DOI
4 Rocha EP, Xu X, Hall HE, Allen JR, Regnery HL, Cox NJ. 1993. Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J. Gen. Virol. 74: 2513-2518.   DOI
5 Schild G, Oxford J, De Jong J, Webster R. 1983. Evidence for host-cell selection of influenza virus antigenic variants. Nature 303: 706-709.   DOI
6 Dumitrescu M, Grobnicu M, Zilisteanu E, Alexandrescu V. 1981. A three years experience in using MDCK cell line for influenza virus isolation (1979-1981). Arch. Roum. Pathol. Exp. Microbiol. 40: 313.
7 Gambaryan AS, Karasin AI, Tuzikov AB, Chinarev AA, Pazynina GV, Bovin NV, et al. 2005. Receptor-binding properties of swine influenza viruses isolated and propagated in MDCK cells. Virus Res. 114: 15-22.   DOI
8 Stevens J, Chen L-M, Carney PJ, Garten R, Foust A, Le J, et al. 2010. Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J. Virol. 84: 8287-8299.   DOI
9 Pradesh A. 2012. Novartis receives FDA approval for Flucelvax, the first cell-culture vaccine in US to help protect against seasonal influenza. Available from http://www.andhranews.net/Business/2012/Novartis-receives-FDA-approval-Flucelvax-first-53291.htm. Accessed Nov. 20, 2012.
10 Tanzi MG. 2013. Flucelvax: first seasonal vaccine using cellculture technology. Pharm. Today 19: 31.   DOI
11 Ping J, Lopes TJ, Nidom CA, Ghedin E, Macken CA, Fitch A, et al. 2015. Development of high-yield influenza A virus vaccine viruses. Nat. Commun. 2: 8148.
12 Hale BG, Randall RE, Ortín J, Jackson D. 2008. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 89: 2359-2376.   DOI
13 Watanabe T, Imai M, Kawaoka Y. 2017. NS1 is the fluid for "flu-transmission". Proc. Natl. Acad. Sci. USA 2017 114: 11012-11014.   DOI
14 Genzel Y, Olmer R, Schafer B, Reichl U. 2006. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 24: 6074-6087.   DOI
15 Hu AYC, Weng TC, Tseng YF, Chen YS, Wu CH, Hsiao S, et al. 2008. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine 26: 5736-5740.   DOI
16 Merten O, Manuguerra J, Hannoun C. 1999. Production of influenza virus in serum-free mammalian cell cultures. Dev. Biol. Stand. 98: 73-24.
17 Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. 2001. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19: 3444-3450.   DOI
18 Hannoun C. 2013. The evolving history of influenza viruses and influenza vaccines. Expert Rev. Vaccines 12: 1085-1094.   DOI
19 Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. 2009. Antigenic and genetic characteristics of swineorigin 2009 A (H1N1) influenza viruses circulating in humans. Science 325: 197-201.   DOI
20 Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, et al. 2010. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28: 840-848.   DOI
21 Saito T, Nakaya Y, Suzuki T, Ito R, Saito T, Saito H, et al. 2004. Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J. Med. Virol. 74: 336-343.   DOI
22 Grohskopf LA, Olson SJ, Sokolow LZ, Bresee JS, Cox N, Broder KR, et al. 2016. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP)-United States, 2016-17 influenza season. MMWR Recomm. Rep. 65: 1-54.
23 Murakami S, Horimoto T, Yamada S, Kakugawa S, Goto H, Kawaoka Y. 2008. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J. Virol. 82: 1605-1609.   DOI
24 Qiao C, Tian G, Jiang Y, Li Y, Shi J, Yu K, et al. 2006. Vaccines developed for H5 highly pathogenic avian influenza in China. Ann. N.Y. Acad. Sci. 1081: 182-192.   DOI
25 Shi H, Liu XF, Zhang X, Chen S, Sun L, Lu J. 2007. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses. Vaccine 25: 7379-7384.   DOI
26 Roy P, Noad R. 2009. Virus-like particles as a vaccine delivery system: myths and facts. Adv. Exp. Med. Biol. 655: 145158.
27 Gabriel G, Abram M, Keiner B, Wagner R, Klenk H-D, Stech J. 2007. Differential polymerase activity in avian and mammalian cells determines host range of influenza virus. J. Virol. 81: 9601-9604.   DOI
28 Lee M-S, Hu AY-C. 2012. A cell-based backup to speed up pandemic influenza vaccine production. Trends Microbiol. 20: 103-105.   DOI
29 Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng P-Y, et al. 2012. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 12: 687-695.   DOI
30 Larson RC, Teytelman A. 2012. Modeling the effects of H1N1 influenza vaccine distribution in the United States. Value Health 15: 158-166.   DOI
31 Gaush CR, Smith TF. 1968. Replication and plaque assay of influenza virus in an established line of canine kidney cells. J. Appl. Microbiol. 16: 588-594.   DOI
32 Ulmer JB, Valley U, Rappuoli R. 2006. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 24: 1377-1383.   DOI
33 Govorkova E, Matrosovich M, Tuzikov A, Bovin N, Gerdil C, Fanget B, et al. 1999. Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells. Virology 262: 31-38.   DOI
34 Audsley JM, Tannock GA. 2008. Cell-based influenza vaccines. Drugs 68: 1483-1491.   DOI
35 Genzel Y, Reichl U. 2009. Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines 8: 1681-1692.   DOI
36 Doroshenko A, Halperin SA. 2009. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 8: 679-688.   DOI
37 Song M-S, Baek YH, Pascua PNQ, Kwon H-I, Park S-J, Kim E-H, et al. 2013. Establishment of Vero cell RN A polymerase I-driven reverse genetics for influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production. J. Gen. Virol. 94: 1230-1235.
38 Song JY, Cheong HJ, Lee J, Woo HJ, Wie S-H, Lee J-S, et al. 2015. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): a randomized, double-blind, multi-center, phase 3 clinical trial. Vaccine 33: 5437-5444.   DOI
39 HSA. 2014. Understanding vaccines, vaccine development and production. Available from http://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Consumer_Information/Public_Advisories/Influenza_A_H1N1_information/H1N1_Vaccines/understanding-vaccines--vaccine-developmentand-production.html. Accessed Sep. 24, 2012.
40 Shin D, Park KJ, Lee H, Cho EY, Kim MS, Hwang MH, et al. 2015. Comparison of immunogenicity of cell- and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines. Virus Res. 204: 40-46.   DOI